Posttraumatic Stress Disorder Author: Jeffrey P. Staab, MD, MS
Editorial changes - 2009-10-13
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up
Tables
References
Glossary
What's New
Patient Information
Additional Resources
Tools
Patient Education
  • Describe PTSD as a specific illness, not simply a patient's inability to “get over” a traumatic event.
  • Explain psychotherapy and medication treatments for PTSD.

Describe PTSD as a specific illness, not simply a patient's inability to “get over” a traumatic event. C

  • Provide education about the full spectrum of PTSD symptoms and how they relate to the inciting traumatic event.
Background | Back to top


Explain psychotherapy and medication treatments for PTSD. C

  • Inform patients about the existence of specific and effective psychotherapies for PTSD.
  • Discuss the role of medications for reducing, but not eliminating, the symptoms of PTSD.
Background | Back to top

FAQs
Jeffrey P. Staab, MD, MS, is a consultant for Eli Lilly, Forest Laboratories, received honorarium from Abbott Laboratories, received grants from GlaxoSmithKline, Pfizer. Michael Roy, MD, editorial consultant, received honorarium from PFizer.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.

The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.